GlassScriptPhysician profile
Linnette Lopez Lopez
NPI 1942499041
$27,969.03
in general payments reported to CMS, 2019-2025
36 companies · $2,596 in 2025
The $2,596 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,344 · 2020: $6,577 · 2021: $2,915 · 2022: $2,965 · 2023: $3,261 · 2024: $3,312 · 2025: $2,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,079 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,079.01 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $7,974.64 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Horizon Therapeutics Plc | $2,802.21 | 2019-2023 | Krystexxa |
| Abbvie INC. | $2,434.96 | 2019-2025 | |
| Amgen INC. | $2,252.29 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,829.37 | 2019-2025 | |
| Pfizer INC. | $1,632.77 | 2019-2025 | |
| Ucb, INC. | $1,472.38 | 2019-2025 | Bimzelx, Cimzia |
| Radius Health, INC. | $1,257.37 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $908.23 | 2019-2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $711.02 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $677.44 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $645.70 | 2019-2025 | Ofev, Cyltezo |
| Janssen Pharmaceuticals, INC | $577.26 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $564.07 | 2019-2025 | Orencia |
| Genzyme Corporation | $399.90 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $338.20 | 2021-2025 | Saphnelo |
| Mallinckrodt Enterprises LLC | $286.93 | 2019 | |
| Ani Pharmaceuticals, INC. | $208.04 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $198.81 | 2019-2024 | Actemra |
| Aurinia Pharma U.S., INC. | $162.81 | 2021-2025 | Lupkynis |
| Organon LLC | $115.11 | 2023-2024 | Hadlima |
| Sobi, INC | $90.52 | 2019-2025 | |
| Sandoz INC. | $76.36 | 2024-2025 | Hyrimoz, Jubbonti |
| Kiniksa Pharmaceuticals, LTD. | $41.05 | 2022-2023 | Arcalyst |
| Celgene Corporation | $37.64 | 2019 | |
| Alexion Pharmaceuticals, INC. | $37.62 | 2023 | Strensiq |
| Antares Pharma, INC. | $35.88 | 2019 | |
| Medexus Pharma, INC. | $27.10 | 2019 | |
| Tersera Therapeutics LLC | $25.65 | 2022 | |
| Biocon Biologics INC | $24.46 | 2024 | Hulio |
| Vertex Pharmaceuticals Incorporated | $23.41 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $22.53 | 2023 | Truxima |
| Ultragenyx Pharmaceutical INC. | $21.52 | 2021 | |
| Fresenius Kabi USA, LLC | $19.86 | 2023 | |
| Mylan Institutional INC. | $19.44 | 2023 | |
| Bioventus LLC | $16.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linnette Lopez Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.